Zydus Lifesciences gets WHO prequalification for Typhoid Vi conjugate vaccine

Zydus Lifesciences Ltd has received in-principle approval from the WHO for its Typhoid Vi conjugate vaccine, ZyVac TCV. Eligible for UN procurement, the vaccine targets 6-month to 65-year-olds and addresses high typhoid incidence in India, Africa, and Southeast Asia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LPqGtRs
via IFTTT